Patents by Inventor Joel R. Walker

Joel R. Walker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heteroaryl inhibitors of PDE4
    Patent number: 12264169
    Abstract: The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.
    Type: Grant
    Filed: July 11, 2023
    Date of Patent: April 1, 2025
    Assignee: Tetra Discovery Partners
    Inventors: Mark E. Gurney, Timothy J. Hagen, Xuesheng Mo, A. Samuel Vellekoop, Donna L. Romero, Robert Campbell, Joel R. Walker, Lei Zhu
  • Inhibitors of oplophorus luciferase-derived bioluminescent complexes
    Patent number: 12065421
    Abstract: Compounds that may selectively inhibit Oplophorus luciferase-derived bioluminescent complexes, e.g., NanoBiT® bioluminescent complex, are disclosed as well as compositions and kits comprising the compounds, and methods of using the compounds.
    Type: Grant
    Filed: June 15, 2022
    Date of Patent: August 20, 2024
    Assignee: Promega Corporation
    Inventors: Joel R. Walker, Mary Hall, Christopher Todd Eggers, Horacio Lazaro
  • COELENTERAZINE ANALOGUES
    Publication number: 20240150363
    Abstract: Described are coelenterazine analogues, methods for making the analogues, kits comprising the analogues, and methods of using the compounds for the detection of luminescence in luciferase-based assays. For example, the compounds may be used for in vivo imaging.
    Type: Application
    Filed: October 13, 2023
    Publication date: May 9, 2024
    Inventors: Joel R. Walker, Thomas Kirkland, Wenhui Zhou, Harry Tetsuo Uyeda, Robert Hurst, Rachel Friedman Ohana, Chao Gao, Hui Wang
  • COELENTERAZINE ANALOGUES
    Publication number: 20240059697
    Abstract: Described are coelenterazine analogues, methods for making the analogues, kits comprising the analogues, and methods of using the compounds for the detection of luminescence in luciferase-based assays.
    Type: Application
    Filed: May 19, 2023
    Publication date: February 22, 2024
    Inventors: Joel R. Walker, Thomas A. Kirkland, Wenhui Zhou, Mary P. Hall, Harry Tetsuo Uyeda
  • HETEROARYL INHIBITORS OF PDE4
    Publication number: 20230348501
    Abstract: The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.
    Type: Application
    Filed: July 11, 2023
    Publication date: November 2, 2023
    Inventors: Mark E. GURNEY, Timothy J. HAGEN, Xuesheng MO, A. Samuel VELLEKOOP, Donna L. ROMERO, Robert CAMPBELL, Joel R. WALKER, Lei ZHU
  • Heteroaryl inhibitors of PDE4
    Patent number: 11767334
    Abstract: The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.
    Type: Grant
    Filed: June 23, 2022
    Date of Patent: September 26, 2023
    Assignee: Tetra Discovery Partners, LLC
    Inventors: Mark E. Gurney, Timothy J. Hagen, Xuesheng Mo, A. Samuel Vellekoop, Donna L. Romero, Robert Campbell, Joel R. Walker, Lei Zhu
  • Coelenterazine analogues
    Patent number: 11691976
    Abstract: Described are coelenterazine analogues, methods for making the analogues, kits comprising the analogues, and methods of using the compounds for the detection of luminescence in luciferase-based assays.
    Type: Grant
    Filed: August 22, 2019
    Date of Patent: July 4, 2023
    Assignee: Promega Corporation
    Inventors: Joel R. Walker, Thomas A. Kirkland, Wenhui Zhou, Mary P. Hall, Harry Tetsuo Uyeda
  • HETEROARYL INHIBITORS OF PDE4
    Publication number: 20230024240
    Abstract: The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.
    Type: Application
    Filed: June 23, 2022
    Publication date: January 26, 2023
    Inventors: Mark E. GURNEY, Timothy J. HAGEN, Xuesheng MO, A. Samuel VELLEKOOP, Donna L. ROMERO, Robert CAMPBELL, Joel R. WALKER, Lei ZHU
  • INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES
    Publication number: 20220365086
    Abstract: Compounds that may selectively inhibit Oplophorus luciferase-derived bioluminescent complexes, e.g., NanoBiT® bioluminescent complex, are disclosed as well as compositions and kits comprising the compounds, and methods of using the compounds.
    Type: Application
    Filed: June 15, 2022
    Publication date: November 17, 2022
    Inventors: Joel R. Walker, Mary Hall, Christopher Todd Eggers, Horacio Lazaro
  • Heteroaryl inhibitors of PDE4
    Patent number: 11401286
    Abstract: The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.
    Type: Grant
    Filed: February 4, 2020
    Date of Patent: August 2, 2022
    Assignee: Tetra Discovery Partners, LLC
    Inventors: Mark E. Gurney, Timothy J. Hagen, Xuesheng Mo, A. Samuel Vellekoop, Donna L. Romero, Robert Campbell, Joel R. Walker, Lei Zhu
  • Inhibitors of oplophorus luciferase-derived bioluminescent complexes
    Patent number: 11390599
    Abstract: Compounds that may selectively inhibit Oplophorus luciferase-derived bioluminescent complexes, e.g., NanoBiT® bioluminescent complex, are disclosed as well as compositions and kits comprising the compounds, and methods of using the compounds.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: July 19, 2022
    Assignee: Promega Corporation
    Inventors: Joel R. Walker, Mary Hall, Christopher Todd Eggers, Horacio Lazaro
  • TARGET ENGAGEMENT ASSAY FOR RAS PROTEINS
    Publication number: 20220064696
    Abstract: Provided herein are systems, methods, and compounds for identifying RAS binding compounds using a RAS binding agent, which comprises a RAS binding moiety and a functional element. In some embodiments, the RAS binding agent binds to one site on the RAS protein (e.g., KRAS, HRAS, or NRAS), and can be used to detect RAS binding agents that bind to the same site as well as other sites.
    Type: Application
    Filed: August 27, 2021
    Publication date: March 3, 2022
    Applicant: Promega Corporation
    Inventors: Matthew B. Robers, Joel R. Walker, James Vasta, Cesear Corona
  • Cell impermeable coelenterazine analogues
    Patent number: 11192894
    Abstract: Described are coelenterazine analogues, methods for making the analogues, kits comprising the analogues, and methods of using the compounds for the detection of luminescence in luciferase-based assays.
    Type: Grant
    Filed: December 23, 2019
    Date of Patent: December 7, 2021
    Assignee: PROMEGA CORPORATION
    Inventors: Mary Hall, Thomas Kirkland, Poncho Meisenheimer, Rachel Friedman Ohana, Anton Shakhmin, Joel R. Walker, Wenhui Zhou
  • HETEROARYL INHIBITORS OF PDE4
    Publication number: 20200354384
    Abstract: The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.
    Type: Application
    Filed: February 4, 2020
    Publication date: November 12, 2020
    Inventors: Mark E. GURNEY, Timothy J. HAGEN, Xuesheng MO, A. Samuel VELLEKOOP, Donna L. ROMERO, Robert CAMPBELL, Joel R. WALKER, Lei ZHU
  • Functionalized NANOLUC inhibitors
    Patent number: 10815247
    Abstract: Compounds that may inhibit Oplophorus-derived luciferases are disclosed as well as compositions and kits comprising the compounds, and methods of using the compounds.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: October 27, 2020
    Assignee: PROMEGA CORPORATION
    Inventors: Roderick G. Flemming, Mary Hall, Thomas Machleidt, Poncho Meisenheimer, Nidhi Nath, Matthew B. Robers, Joel R. Walker, Wenhui Zhou
  • CELL IMPERMEABLE COELENTERAZINE ANALOGUES
    Publication number: 20200239475
    Abstract: Described are coelenterazine analogues, methods for making the analogues, kits comprising the analogues, and methods of using the compounds for the detection of luminescence in luciferase-based assays.
    Type: Application
    Filed: December 23, 2019
    Publication date: July 30, 2020
    Inventors: Mary Hall, Thomas Kirkland, Poncho Meisenheimer, Rachel Friedman Ohana, Anton Shakhmin, Joel R. Walker, Wenhui Zhou
  • Coelenterazine analogues
    Patent number: 10669280
    Abstract: Described are coelenterazine analogues, methods for making the analogues, kits comprising the analogues, and methods of using the compounds for the detection of luminescence in luciferase-based assays.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: June 2, 2020
    Assignee: PROMEGA CORPORATION
    Inventors: Mary Hall, Thomas Kirkland, Thomas Machleidt, Anton Shakhmin, Joel R. Walker
  • Heteroaryl inhibitors of PDE4
    Patent number: 10626129
    Abstract: The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: April 21, 2020
    Assignee: Tetra Discovery Partners, LLC
    Inventors: Mark E. Gurney, Timothy J. Hagen, Xuesheng Mo, A. Samuel Vellekoop, Donna L. Romero, Robert Campbell, Joel R. Walker, Lei Zhu
  • Cell impermeable coelenterazine analogues
    Patent number: 10577370
    Abstract: Described are coelenterazine analogues, methods for making the analogues, kits comprising the analogues, and methods of using the compounds for the detection of luminescence in luciferase-based assays.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: March 3, 2020
    Assignee: PROMEGA CORPORATION
    Inventors: Mary Hall, Thomas Kirkland, Poncho Meisenheimer, Rachel Friedman Ohana, Anton Shakhmin, Joel R. Walker, Wenhui Zhou
  • THIENOPYRROLE COMPOUNDS AND USES THEREOF
    Publication number: 20200063110
    Abstract: Thienopyrrole compounds that may inhibit Oplophorus-derived luciferases are disclosed, as well as compositions and kits comprising the thienopyrrole compounds, and methods of using the thienopyrrole compounds.
    Type: Application
    Filed: November 5, 2019
    Publication date: February 27, 2020
    Inventors: Sarah Duellman, Matthew B. Robers, Joel R. Walker, Wenhui Zhou, Chad Zimprich